<?xml version="1.0" encoding="UTF-8"?>
<p>This is a critically important juncture for TB vaccine development. Results from the recently concluded BCG revaccination study in South African adolescents at high risk of acquiring 
 <italic>Mtb</italic> infection have reemphasized the potential promise of looking at this old vaccine in new ways 
 <sup>
  <xref rid="ref-12" ref-type="bibr">12</xref>
 </sup>. M72/AS01E candidate vaccine results, published after the meeting reported here, constitute a major encouragement for the field, and argue in favor of strengthening global health stakeholder engagement and funding for further TB vaccine R&amp;D efforts 
 <sup>
  <xref rid="ref-141" ref-type="bibr">141</xref>
 </sup>. Ongoing, robust support for TB vaccine development will be critical to ensuring that a TB vaccine is available to help end the global scourge of tuberculosis.
</p>
